Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985548 | 0.82 | NQO1 (0.42) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL23361704 | 0.77 | ALDH1A1 (0.49) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2119267 | 0.76 | CYP19A1 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL16952456 | 0.75 | SCN4A (0.41) | NQO1ALDH1A1KDM4EGRM5TSHR | |
| SCHEMBL11062080 | 0.75 | SCN5A (0.43) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL25344472 | 0.75 | NQO1 (0.36) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL27514230 | 0.75 | ALDH1A1 (0.42) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10434028 | 0.74 | NQO1 (0.48) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2116816 | 0.73 | ALDH1A1 (0.46) | NQO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL973269 | 0.72 | ALDH1A1 (0.41) | NQO1ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2629767-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | Cleveland State University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054417-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | RB1, BCR, NRAS | NQO1 243/4885ALDH1A1 639/4885KDM4E 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.